The Effect of Cilostazol on Right Heart Function and Pulmonary Pressure. Issue 6 (December 2013)

• Record Type: Journal Article
• Authors: Sahin, Muslum; Alizade, Elnur; Pala, Selcuk; Alici, Gokhan; Ozkan, Birol; Akgun, Taylan; Emiroglu, Yunus; Demir, Serdar; Yazicioglu, Mehmet V.; Turkmen, Mehmet M.
• Is Part Of: Cardiovascular therapeutics. Volume 31:Issue 6(2013:Dec.)
• Page Start: e88
• Page End: e93
• Publication Date: 2013-12
• Subjects: Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals; Cardiovascular Agents -- Periodicals; Cardiovascular Diseases -- drug therapy -- Periodicals; Agents cardiovasculaires -- Périodiques; Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques; 616.1005
• DOI: 10.1111/1755-5922.12041
• Languages: English
• ISSNs: 1755-5914

Abstract

<abstract abstract-type="main" id="cdr12041-abs-0001"> <title>Summary</title> <sec id="cdr12041-sec-0001" sec-type="section"> <title>Introduction</title> <p>Cilostazol is a PDE3 inhibitor and used to treat peripheral arterial disease. There are few reports on the influence of cilostazol on heart.</p> </sec> <sec id="cdr12041-sec-0002" sec-type="section"> <title>Aims</title> <p>The aim of this study was to assess this effect on right ventricular function and pulmonary artery pressure.</p> </sec> <sec id="cdr12041-sec-0003" sec-type="section"> <title>Methods</title> <p>Forty patients with normal left and right ventricular ejection fraction and mild or moderate pulmonary artery hypertension were enrolled in the study. Right ventricular function was assessed by tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), tissue Doppler imaging (TDI), and two‐dimensional speckle‐tracking echocardiography (2D‐STE) before and after oral administration of cilostazol. Also pulmonary artery pressure assessed before and after administration of cilostazol.</p> </sec> <sec id="cdr12041-sec-0004" sec-type="section"> <title>Results</title> <p>After cilostazol administration, there were significant increases in the TAPSE (1.9 ± 0.3 cm vs. 2.2 ± 0.3 cm, <italic>P </italic>< 0.001). Peak longitudinal strain (−18.7 ± 4.5% vs. −21.3 ± 3.7%, <italic>P</italic> = 0.001), isovolumetric acceleration (IVA) (176.6 ± 62.7 cm/sec<sup>2</sup> vs. 200.6 ± 61.9 cm/sec<sup>2</sup>, <italic>P</italic> = 0.025), right ventricular FAC increased significantly (37.6 ± 8.0% vs. 41.5 ± 8.9%, <italic>P </italic>< 0.001). Pulmonary artery pressure decreased significantly (39.9 ± 7.9 vs. 36.6 ± 5.5 mmHg, <italic>P</italic> = 0.001) after cilostazol administration.</p> </sec> <sec id="cdr12041-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Our study demonstrated that cilostazol improved right ventricular systolic function and reduced pulmonary artery pressure.</p> </sec> </abstract>